Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and PAVmed subsidiary, announces a business update conference call and webcast scheduled for November 13, 2024, at 8:30 AM ET. Chairman and CEO Lishan Aklog will provide operational updates and growth strategy insights, while CFO Dennis McGrath will present Q3 2024 financial results.

The webcast will be accessible through the company's investor relations website at luciddx.com. U.S. callers can dial 1-800-836-8184, and international callers 1-646-357-8785, referencing 'Lucid Diagnostics Business Update' to join. A 30-day replay will be available on the company website afterward.

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, October 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2024 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-13-2024-302291335.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) Q3 2024 earnings call?

Lucid Diagnostics (LUCD) will hold its Q3 2024 business update conference call and webcast on November 13, 2024, at 8:30 AM Eastern Time.

How can I listen to Lucid Diagnostics (LUCD) November 2024 earnings call?

You can access the call through the webcast at luciddx.com, dial 1-800-836-8184 (U.S. callers) or 1-646-357-8785 (international callers), mentioning 'Lucid Diagnostics Business Update'.

How long will Lucid Diagnostics (LUCD) November 2024 earnings call replay be available?

The conference call replay will be available for 30 days on Lucid Diagnostics' investor relations website at luciddx.com.

What topics will be covered in Lucid Diagnostics (LUCD) November 2024 business update?

The call will cover company operations, growth strategy, and third quarter 2024 financial results, presented by CEO Lishan Aklog and CFO Dennis McGrath.